Tech Transfer eNews Blog

Yissum inks license for cannabinoid-based nasal drug delivery technology to treat neurological conditions

By Jesse Schwartz
Published: April 12th, 2017

Yissum Research Development Company, the tech transfer arm of Hebrew University of Jerusalem, has signed a license agreement with Therapix Biosciences, a specialty clinical-stage pharmaceutical company focused on cannabinoid-based drugs, to commercialize a nasal drug delivery technology.

Developed by professor Elka Touitou of the Institute of Drug Research at Hebrew University, the technology effectively administers nasal absorption of tetrahydrocannabinol (TCH), the key pharmaceutical ingredient in Therapix’s drug development pipeline.

Under the agreement, Yissum will grant Therapix an exclusive, global, sub-licensable, royalty-bearing license to the innovation. Therapix CEO Elran Haber says the agreement will pave the way for the development and commercialization of cannabinoid-based treatments for patients suffering from a range of neurological conditions.

“Compared with standard oral administration, we expect the nasal delivery technology developed by professor Touitou and her team at Hebrew University to offer improved bioavailability, efficacy and a shorter reaction time for patients,” says Haber.

Source: PR Newswire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment